1. Home
  2. LCFY vs BIAF Comparison

LCFY vs BIAF Comparison

Compare LCFY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$2.47

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$7.85

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
BIAF
Founded
2009
2014
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
9.2M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
LCFY
BIAF
Price
$2.47
$7.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.4K
★ 7.0M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.49
52 Week Low
$2.10
$0.33
52 Week High
$7.67
$20.35

Technical Indicators

Market Signals
Indicator
LCFY
BIAF
Relative Strength Index (RSI) 54.81 53.42
Support Level $2.50 $1.07
Resistance Level $2.73 $12.48
Average True Range (ATR) 0.16 1.56
MACD 0.03 -0.37
Stochastic Oscillator 68.64 28.16

Price Performance

Historical Comparison
LCFY
BIAF

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: